United States
£ GBP
This third volume in the successful Drug Discovery in Infectious Diseases'series is the first to deal with drug discovery in helminthic infections in human and animals. The result is a broad overview of different drug target evaluation methods, including specific examples of successful drug development against helminthes, and with a whole section devoted to vaccine development. With its well-balanced mix of high-profile contributors from academia and industry, this handbook and reference will appeal to a wide audience, including parasitologists, pharmaceutical industry, epidemiologists, and veterinary scientists.
Conor R. Caffrey completed his Ph.D. thesis research in 1993 at University College Dublin. He then moved to the Department of Tropical Medicine and Hygiene at the University of Heidelberg as a Wellcome Trust Travelling Research Scholar. Between 1998 and 2000, he was a post-doctoral scholar at the Department of Pathology of the University of California San Francisco. After a brief faculty appointment at the University of Wales, Aberystwyth, Dr. Caffrey returned to UCSF in 2001 to direct the Biochemistry and Molecular Parasitology Core of the Sandler Center the Sandler Center for Basic Research in Parasitic Diseases (now the Sandler Center for Drug Discovery). Dr. Caffrey?s current research focus is pre-clinical drug discovery for tropical infectious diseases, particularly schistosomiasis and African trypanosomiasis.
Prof. Dr. Paul M. Selzer studied Biology, Parasitology, and Biochemistry at the University of Tubingen, Germany, where he also received his PhD in Biochemistry on subjects related to the protozoan parasite Trypanosoma brucei. As a post-doctoral fellow he spent three years in the parasitology and tropical disease laboratory of Prof. James H. McKerrow at the University of California, San Francisco (UCSF). Within the Molecular Design Institute at UCSF Dr. Selzer was introduced to modern drug discovery approaches and technologies. He broadened his scientific and business knowledge as a researcher within diverse pharmaceutical companies including Boehringer Mannheim GmbH, Germany, SmithKline Beecham p.l.c., UK, Hoechst Roussel Vet GmbH, Germany, and finally Intervet Innovation GmbH, Germany, a part of Intervet/Schering-Plough Animal Health. Dr. Selzer is also a teacher in Biochemistry, Bioinformatics, and Chemoinformatics at the University of Tubingen in the Department of Biochemistry, which awarded him the title of Professor for his achievements in teaching and research. In 2008, he was also awarded an Honorary Professorship in the Department of Infection and Immunity at the University of Glasgow, UK.
